- Inicio
- Publicaciones
- Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial
Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Cortes, JE
- Khaled, SK
- Martinelli, G
- Perl, AE
- Ganguly, S
- Russell, NH
- Kramer, A
- Dombret, H
- Hogge, D
- Jonas, BA
- Leung, AYH
- Mehta, P
- Radsak, MP
- Sica, S
- Arunachalam, M
- Holmes, M
- Kobayashi, K
- Namuyinga, R
- Ge, NX
- Yver, A
- Zhang, YF
- Levis, MJ
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 6,065 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Portal de investigación